MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shiah, S.-G.
Right arrow Articles by Kuo, M.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shiah, S.-G.
Right arrow Articles by Kuo, M.-L.

Vol. 59, Issue 2, 254-262, February 2001

Involvement of Asp-Glu-Val-Asp-Directed, Caspase-Mediated Mitogen-Activated Protein Kinase Kinase 1 Cleavage, c-Jun N-Terminal Kinase Activation, and Subsequent Bcl-2 Phosphorylation for Paclitaxel-Induced Apoptosis in HL-60 Cells

Shine-Gwo Shiah, Shuang-En Chuang, and Min-Liang Kuo

Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan (S.-G.S., M.-L.K.); and Division of Cancer Research, National Health Research Institute, Taipei, Taiwan (S.-E.C.)

Paclitaxel is a novel anticancer drug that has demonstrated efficacy toward treating several malignant tumor types. Here, we demonstrate that c-Jun NH2-terminal kinase (JNK), but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2, was persistently activated by paclitaxel or other microtubule-damaging agents within human leukemia HL-60 cells. Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis. Furthermore, we found that the full-length MEKK1 was cleaved to a 91-kDa carboxyl-terminal fragment at the earlier time of apoptosis induced by microtubule-damaging agents. This cleavage, however, occurred consistently with JNK activation and Bcl-2 phosphorylation, but preceded DNA fragmentation in cells in response to paclitaxel activity. The caspase inhibitor Ac-Asp-Glu-Val-Asp-CHO (DEVD-CHO), but not Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO), effectively blocked MEKK1 cleavage, JNK activation, Bcl-2 phosphorylation, and subsequent apoptosis. Subcellular fractionation revealed that the 91-kDa C-terminal MEKK1 fragment was translocated to cytosol. Notably, the MEKK1 fragment could be coimmunoprecipitated with anti-JNK antibodies, suggesting that a signaling complex of C-terminal MEKK1/stress-activated protein kinase/extracellular-signal regulated kinase 1/JNK formed during apoptosis induced by microtubule-damaging agents. Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
CarcinogenesisHome page
J.-L. Su, M.-T. Lin, C.-C. Hong, C.-C. Chang, S.-G. Shiah, C.-W. Wu, S.-T. Chen, Y.-P. Chau, and M.-L. Kuo
Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells
Carcinogenesis, January 1, 2005; 26(1): 1 - 10.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer
Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1084 - 1095.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
V. M. Pushkarev, D. V. Starenki, V. A. Saenko, H. Namba, J. Kurebayashi, M. D. Tronko, and S. Yamashita
Molecular Mechanisms of the Effects of Low Concentrations of Taxol in Anaplastic Thyroid Cancer Cells
Endocrinology, July 1, 2004; 145(7): 3143 - 3152.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
R. E. Brown and J. L. Boyle
Mesenchymal Chondrosarcoma: Molecular Characterization by a Proteomic Approach, with Morphogenic and Therapeutic Implications
Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 131 - 141.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Kwan, J. Burnside, T. Kurosaki, and G. Cheng
MEKK1 Is Essential for DT40 Cell Apoptosis in Response to Microtubule Disruption
Mol. Cell. Biol., November 1, 2001; 21(21): 7183 - 7190.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics